In the context of MM, bortezomib and the B-cell maturation antigen (BCMA)-targeting antibody–drug conjugate belantamab mafodotin trigger ICD through surface expression of both HSP90 and CRT [5,15,16]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.